Franklin Biotechnology Discovery Fund Class R6 (FRBRX) - Health fund with $1.42 Billion in assets. The fund allocates 37.49% of its portfolio to its top 10 holdings. It primarily invests in averagemarketcap cap stocks , with a focus on the cash and equivalents sector.
The largest holding in the fund is Amgen, Inc. at 4.49% of total assets. This is followed by Regeneron Pharmaceuticals, Inc. (4.09%) and Vertex Pharmaceuticals, Inc. (4.56%).
| Name | Weight | Owned | Change |
|---|---|---|---|
| Amgen, Inc. | 4.49% | - | - |
| Regeneron Pharmaceuticals, Inc. | 4.09% | - | - |
| Vertex Pharmaceuticals, Inc. | 4.56% | - | - |
| Insmed, Inc. | 3.75% | - | - |
| Ascendis Pharma A/S | 3.10% | - | - |
| Gilead Sciences, Inc. | 5.57% | - | - |
| Intra-Cellular Therapies, Inc. | 2.97% | - | - |
| Institutional Fiduciary Trust Money Market Portfolio | 2.97% | - | - |
| Biogen, Inc. | 2.93% | - | - |
| AstraZeneca plc | 3.06% | - | - |
| Institutional Fiduciary Trust - Money Market Portfolio | 3.85% | - | - |
| Argenx SE | 4.14% | - | - |
| Jazz Pharmaceuticals plc | 4.02% | - | - |
| Neurocrine Biosciences, Inc. | 3.15% | - | - |
| Alnylam Pharmaceuticals, Inc. | 3.83% | - | - |
| Franklin Institutional U.S. Government Money Market Fund | 3.47% | - | - |